中线（NUT）癌诊断与治疗专家共识（2023版）

doi:10.3969/j.issn.1674-5671.2023.05.01

Chinese Journal of Oncology Prevention and Treatment ›› 2023, Vol. 15 ›› Issue (5): 463-476.doi: 10.3969/j.issn.1674-5671.2023.05.01

Online:2023-10-25 Published:2023-11-03

Abstract

CLC Number:

R730

NUT Carcinoma Diagnosis Working Group of the Chinese Anti-Cancer Association's Oncogene Diagnosis. Expert consensus on the diagnosis and treatment of midline (NUT) carcinoma (2023 Edition)[J].Chinese Journal of Oncology Prevention and Treatment, 2023, 15(5): 463-476.

[1]	The Society of Medical Ethics of China Anti⁃Cancer Association. Chinese expert consensus on compensation management for research participants in clinical trials of cancer (2024 edition) [J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 650-655.
[2]	NIE Shihao, LIU Hao, LU Yuanyuan. Role and mechanism of non⁃coding RNA on EGFR and related signaling pathways in tumors [J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(5): 564-568.

Expert consensus on the diagnosis and treatment of midline (NUT) carcinoma (2023 Edition)

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 2

Metrics

Comments

Recommended 0